Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

AstraZeneca halts Phase III trials for kidney disease treatment

Published Dec 01, 2023 07:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
AZN
+0.72%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
+0.64%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

AstraZeneca (NASDAQ:AZN) plc has announced the discontinuation of its Phase III STABILIZE-CKD and DIALIZE-Outcomes trials, which were investigating treatments for chronic kidney disease (CKD) due to prolonged enrolment periods and low event rates. Despite this setback, the pharmaceutical giant reaffirms its commitment to addressing hyperkalaemia, a condition commonly associated with CKD, through its globally approved potassium binder, Lokelma.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, assured that Lokelma maintains a strong safety profile and continues to deliver substantial benefits to patients dealing with hyperkalaemia. The drug is currently approved in 56 countries around the world.

AstraZeneca has also committed to ensuring that patients from the halted trials will continue to receive follow-up care. The company's CVRM (Cardiovascular, Renal and Metabolism) sector remains focused on advancing treatments that protect organs affected by cardiorenal diseases and is working towards the development of regenerative therapies in this field.

InvestingPro Insights

AstraZeneca's recent decisions in clinical trials reflect a strategic pivot, but their financial health, as indicated by real-time data from InvestingPro, remains robust. The company's market capitalization stands at a substantial 199.8 billion USD, showcasing its significant presence in the pharmaceutical industry. Additionally, AstraZeneca boasts an impressive gross profit margin of 89.17% over the last twelve months as of Q3 2023, reflecting efficient operations and strong pricing power.

InvestingPro Tips highlight AstraZeneca's high earnings quality, with free cash flow exceeding net income, and a high return on invested capital, underscoring the company's ability to generate profits from its investments. These factors are critical for investors considering the company's potential for sustained financial performance, especially in light of recent clinical trial updates.

For those looking to delve deeper into AstraZeneca's financials and future outlook, the InvestingPro platform offers additional insights. There are 18 more InvestingPro Tips available for AstraZeneca, providing a comprehensive analysis of the company's financial health and market position. With the special Cyber Monday sale, subscribers can now access these valuable tips at a discount of up to 60%, and using the coupon code sfy23 will grant an extra 10% off a 2-year InvestingPro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

AstraZeneca halts Phase III trials for kidney disease treatment
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email